Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report

Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib mig...

Descripción completa

Detalles Bibliográficos
Autores principales: Osugi, Jun, Owada, Yuki, Yamaura, Takumi, Muto, Satoshi, Okabe, Naoyuki, Matsumura, Yuki, Higuchi, Mitsunori, Suzuki, Hiroyuki, Gotoh, Mitsukazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Published online: January, 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748772/
https://www.ncbi.nlm.nih.gov/pubmed/26933419
http://dx.doi.org/10.1159/000443662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748772/
https://www.ncbi.nlm.nih.gov/pubmed/26933419
http://dx.doi.org/10.1159/000443662

Ejemplares similares